Portfolio companies news

12 January 2014

Medicare Part D is saving lives

Patrick Muraca, News Telegram.com

Cambridge-based Syndax Pharmaceuticals recently received coveted "breakthrough therapy" status for a promising late-stage breast cancer drug. The designation expedites the development and approval of the drug, Entinostat, in the hope of saving more lives sooner.

18 December 2013

Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that Deepak L. Bhatt, M.D., M.P.H., F.A.C.C., F.A.H.A., has joined the Company's Medical Advisory Board. Regado will benefit from Dr. Bhatt's expertise in cardiovascular intervention and years of experience leading international cardiovascular clinical trials, as the Company actively enrolls patients in its Phase 3 REGULATE-PCI study and positions REG-1 as a potential standard of care for anticoagulant use in percutaneous coronary intervention procedures.

12 December 2013

Venter Pharma und NovaMedica unterzeichnen Vertrag für die Vermarktung eines neuen Tests für die Diagnose von Laktose-Intoleranz in Russland

PHARMA-ZEITUNG.DE

NovaMedica LLC, ein russisches Pharmaunternehmen, und Venter Pharma SL, ein spanisches Unternehmen, das innovative diagnostische Systeme entwickelt, haben eine Partnerschaftsvereinbarung unterzeichnet, im Rahmen derer NovaMedica die Exklusivrechte erhält, um LacTEST®, eine neue Technologie für die Diagnose von Laktose-Intoleranz in Russland und der GUS (Gemeinschaft unabhängiger Staaten) zu vermarkten.

12 December 2013

Venter Pharma y Novamedica, acuerdo de distribución de LacTest en Rusia

PMFARMA

LacTEST es un producto best-in-class de su categoría para el diagnóstico de la intolerancia a la lactosa en individuos de distintos grupos de edad. El test tiene aplicaciones en gastroenterología clínica y ha sido aprobado para su distribución en España y Alemania.

09 December 2013

Regado Biosciences strengthens executive leadership

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Michael A. Metzger to its executive management team, where he will serve as President and Chief Operating Officer.  In this role, he will oversee corporate and business development strategy and planning, as well as other key business functions of the company.  Mr. Metzger was previously Executive Vice President and Chief Operating Officer at Mersana Therapeutics.

03 December 2013

Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma

Tragara Pharmaceuticals, Inc. today announced the initiation of a phase 1b clinical trial of TG02, in combination with the poteosome inhibitor carfilzomib (Kyprolis®), in patients with relapsed or refractory multiple myeloma. TG02 is a potent oral inhibitor of CDK9, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis across a wide range of tumor cells. The study is being led by Craig C. Hofmeister, M.D., at The Ohio State University Comprehensive Cancer Center, and is open for enrollment at multiple centers in the U.S.

21 November 2013

Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced the appointment of Lincoln Krochmal, M.D., as Chief Medical Officer. This appointment reflects the continued growth of Lithera as it prepares to enter late-stage clinical trials and to commercialize its lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection).

18 November 2013

Regado Biosciences, Inc. adds global pharmaceutical business veteran to board of directors

Pierre Legault, MBA, CA, CPA, Brings Substantial Management and Board Expertise to Regado

05 November 2013

Regado Biosciences, Inc. appoints world-renowned leader in cardiovascular research and former global head of cardiovascular diseases for Merck & Co., to Board of Directors

Michael Mendelsohn, M.D. Strengthens Regado's Scientific and Development Expertise as Company Advances Phase 3 REGULATE-PCI Trial.

03 November 2013

Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.